Prognostic Value of [¹⁷⁷Lu]Lu-PSMA SPECT and Timing of RECIP Assessment in mCRPC (EANM 2026) - Sep 29, 2026 - Abstract #OP-461; Pres time: Oct 19, 2026; 03:00 PM - 04:30 PM; Location: Hall G1; "Aim/Introduction: [¹⁷⁷Lu]Lu-PSMA-617 is an established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC)... [¹⁷⁷Lu]Lu-PSMASPECT provides clinically relevant prognostic information beyond clinical parameters. New lesion appearance is the most robust early biomarker of OS. Although RECIP is more predictive at C3, overall performance is similar between C2 and C3."
Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Prostate Cancer • Solid Tumor
|
|
A. Bekkhoucha 1; T. Zaragori 2; P. Olivier 1; M. Claudin 1; P. Marie 1; J. kunsch 1; A. Verger 1; S. Heyer 1; L. Imbert 1; C. Boursier 1
|